Simplify Logo
Sanofi

Sanofi

Global pharma company; vaccines and R&D

Area Business Director

Full-TimeDeadline 10/1/26
$148.5k - $247.5k/yr
Expert
Bachelor's, Master's
Los Angeles, CA, USA
Remote

Remote within the US; regular travel within the division may include frequent overnight and weekend travel.

About the job

Requirements
  • A Bachelor's degree is required.
  • A minimum of 10 years of related sales experience is required, preferably in business-to-business and/or healthcare sales.
  • A minimum of 3–5 years of first-line pharmaceutical sales leadership experience is required.
  • Ability to develop strong, professional relationships for scientific exchange and promotion with healthcare providers in the community.
  • Strong leadership skills, demonstrated commitment to coaching and people development, team-building ability, and inspirational and motivational leadership.
  • Ability to work collaboratively with others, influence peers, and educate management regarding account needs.
  • Strong customer-facing skills and demonstrated negotiating capability.
  • An inclusive and diverse mindset in talent development, promotion, team dynamics, and culture.
  • Excellence in demonstrating personal leadership and serving as a role model aligned with company core values and Play to Win behaviors.
  • Ability to travel within the division regularly, including frequent overnight and weekend travel.
  • A valid driver's license and safe driving record are required.
Responsibilities
  • Lead a division team of Area Business Managers to build customer trust and demonstrate value in a business-to-business selling environment.
  • Develop divisional business plans that break down business targets by products, customer segments, and contracting modalities.
  • Direct Area Business Managers strategically in acquiring, expanding, and retaining targeted customer accounts within the assigned area.
  • Drive implementation of Area Business Manager customer plans using promotional and analytical tools to improve efficiency in the assigned sales geography.
  • Support Area Business Managers in evaluating and prioritizing business across Pediatrics, Family/General Practice, integrated delivery networks and integrated health networks, health systems, and Federally Qualified Health Centers.
  • Lead the team in delivering account performance objectives by developing account plans aligned with regional goals and positioning brands with key accounts using disease-state knowledge.
  • Use account data and multiple territory-level data sources to develop actionable business plans and conduct business reviews.
  • Support teams in navigating and communicating complex contracting and pricing to maintain and expand sales with targeted customer accounts.
  • Establish and track territory performance metrics to evaluate progress, performance, opportunities, and the need to adjust plans and tasks.
  • Coach and train team members to identify business opportunities and key points of contact.
  • Collaborate with cross-functional teams to prioritize account projects and initiatives addressing changing customer and market needs.
  • Present partnership opportunities to the Hospital and Strategic Accounts team and coordinate project implementation.
  • Coordinate with other customer teams to inform customer strategy and share information and insights proactively.
  • Recruit, select, train, and coach team members, ensuring appropriate staffing and competencies.
  • Build and maintain employee morale and motivation and encourage Area Business Manager development, including career development.
Desired Qualifications
  • An advanced or master's degree.
  • Specific knowledge of vaccine sales or buy-and-bill, distribution, administration, and reimbursement.
  • Launch experience within the last four years.
  • Experience with organized customers and delivering an executive value proposition for acute-care or vaccine products.
  • Knowledge of managed-market dynamics and the competitive landscape in the acute-care and/or vaccine space.
  • Exposure to or experience in Sales Training, Customer Solutions, Sales Operations, Managed Care, or Marketing.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.